Dr. Ran Reshef, MD
Claim this profileColumbia University Irving Medical Center
Studies Lymphoma
Studies Adult T-Cell Leukemia/Lymphoma
19 reported clinical trials
30 drugs studied
About Ran Reshef, MD
Education:
- Obtained an MD from Columbia University College of Physicians and Surgeons in 2006.
- Completed a Residency in Internal Medicine at NewYork-Presbyterian Hospital/Columbia University Medical Center in 2009.
- Finished a Fellowship in Hematology and Oncology at NewYork-Presbyterian Hospital/Columbia University Medical Center in 2012.
Experience:
- Currently serves as an Assistant Professor of Medicine at Columbia University Irving Medical Center.
- Attending physician at NewYork-Presbyterian Hospital/Columbia University Medical Center.
Area of expertise
1Lymphoma
CD19 positive
HLA-A negative
HLA-A positive
2Adult T-Cell Leukemia/Lymphoma
HLA-A negative
HLA-A positive
HLA positive
Affiliated Hospitals
Clinical Trials Ran Reshef, MD is currently running
Tabelecleucel
for Post-Transplant Cancer
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab (SOT-R) and rituximab plus chemotherapy (SOT-R+C) or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
Recruiting2 awards Phase 312 criteria
GM T Cell Therapy Long-Term Follow-Up
for Cancer
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Recruiting1 award Phase 2 & 3
More about Ran Reshef, MD
Clinical Trial Related3 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Ran Reshef, MD has experience with
- Fludarabine
- Cyclophosphamide
- Tabelecleucel
- Lenalidomide
- Idecabtagene Vicleucel
- PBCAR0191
Breakdown of trials Ran Reshef, MD has run
Lymphoma
Adult T-Cell Leukemia/Lymphoma
Non-Hodgkin's Lymphoma
Cancer
Multiple Myeloma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Ran Reshef, MD specialize in?
Is Ran Reshef, MD currently recruiting for clinical trials?
Are there any treatments that Ran Reshef, MD has studied deeply?
What is the best way to schedule an appointment with Ran Reshef, MD?
What is the office address of Ran Reshef, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.